Literature DB >> 1139856

Unaltered metabolism of antipyrine and tolbutamide in fasting man.

M M Reidenberg, E S Vesell.   

Abstract

Effects of fasting on the metabolsim and distribution of antipyrine and tolbutamide were studied in 13 obese, but otherwise healthy, volunteers. Only 6 of the 13 subjects decreased their metabolic clearance rate (MCR) during fasting; no significant change occurred during fasting in the mean MCR of either drug. These results are in contrast with reported changed rates of drug metabolism in fasting experimental animals. The apparent volume of distribution (aVd) of antipyrine decreased during fasting in each of 7 subjects receiving oral test doses of antipyrine; the mean control value plus or minus standard deviation was 61 plus or minus 16 1, whereas during fasting the mean became 52 plus or minus 17 1. The aVd plus or minus SD of tolbutamide decreased in 4 of the 6 volunteers receiving intravenous test doses of tolbutamide; the mean control value in these6 volunteers was 8.3 plus or minus 1.7 1; during fasting it was 7.4 plus or minus 1.91.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1139856     DOI: 10.1002/cpt1975176650

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

Review 1.  Effect of dietary protein on renal tubular clearance of drugs in humans.

Authors:  G D Park; R Spector; T M Kitt
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

2.  Interactions between nutritional factors and drug biotransformations in man.

Authors:  A P Alvares; K E Anderson; A H Conney; A Kappas
Journal:  Proc Natl Acad Sci U S A       Date:  1976-07       Impact factor: 11.205

3.  The effect of dietary energy and protein deficiency on drug metabolism.

Authors:  O Hamberg; L Ovesen; A Dorfeldt; S Loft; J Sonne
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Influence of a very low calorie diet on the clearance of oxazepam and antipyrine in man.

Authors:  J Sonne; J Dragsted; S Loft; M Døssing; F Andreasen
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism.

Authors:  G I Adebayo; H A Coker
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Further observations on relationships between antipyrine half-life, clearance and volume of distribution: an appraisal of alternative kinetic parameters used to assess the elimination of antipyrine.

Authors:  L G Sultatos; B H Dvorchik; E S Vesell; D G Shand; R A Branch
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

7.  Dietary influences on the kinetics of antipyrine and aminopyrine in human subjects.

Authors:  K Krishnaswamy; R Kalamegham; N A Naidu
Journal:  Br J Clin Pharmacol       Date:  1984-02       Impact factor: 4.335

Review 8.  Influences of diet and nutrition on clinical pharmacokinetics.

Authors:  K E Anderson
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

9.  Microsomal enzymes in malnutrition as determined by plasma half life of antipyrine.

Authors:  K Krishnaswamy; A N Naidu
Journal:  Br Med J       Date:  1977-02-26

10.  Plasma levels of parent drug and metabolites in the intravenous aminopyrine breath test.

Authors:  U Breyer-Pfaff; M Harder; E H Egberts
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.